1. Short title This Act may be cited as the Better Pain Management Through Better Data Act of 2018 . 2. Guidance addressing alternative approaches to data collection and labeling claims for opioid sparing (a) In general For purposes of assisting sponsors in collecting and incorporating opioid-sparing data in product labeling, the Secretary of Health and Human Services (referred to in this section as the Secretary ) shall conduct a public meeting and update or issue one or more guidances in accordance with subsection (b). (b) Guidance (1) In general The Secretary of Health and Human Services, acting through the Commissioner of Food and Drugs, shall update or issue one or more guidances addressing— (A) alternative methods for data collection on opioid sparing; (B) alternative methods for inclusion of such data in product labeling; and (C) investigations other than clinical trials, including partially controlled studies and objective trials without matched controls such as historically controlled analyses, open-label studies, and meta-analyses, on opioid sparing for inclusion in product labeling. (2) Contents The guidances under paragraph (1) shall address— (A) innovative clinical trial designs for ethically and efficiently collecting data on opioid sparing for inclusion in product labeling; (B) primary and secondary endpoints for the reduction of opioid use while maintaining adequate pain control; (C) use of real world evidence, including patient registries, and patient reported outcomes to support inclusion of opioid-sparing data in product labeling; and (D) how sponsors may obtain feedback from the Secretary relating to such issues prior to— (i) commencement of such data collection